In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Outlook 2024

Annual Industry Ranking And Forecast

The Long Learning Curve For Artificially Intelligent Drug Manufacturing Begins Now

Executive Summary

Drugmakers quickly adopt low-impact AI/ML models in quest to eventually automate manufacturing processes. Already, they are learning a lot about how these models can support their operations. One finding: innovative change management approaches may be required to unlock their full potential.

You may also be interested in...

Safety Limits On AI Could Emerge From US And International Initiatives

Guardrails protecting the public from artificial intelligence and machine learning systems are under development in the US and internationally. Whether they will inhibit global pharmaceutical manufacturers remains an open question that is sure to be discussed in the months and years ahead.

How Drug Manufacturing Experts Are Navigating Artificial Intelligence Hype

There are so many ways to use artificial intelligence to boost the quality of drug products, but which ones are overblown, misconstrued or inappropriate for the problem you are trying to solve? Here’s how some experts are working through these challenges.

Explaining The Unexplainable: How To Win US FDA’s Trust In Artificially Intelligent Drug Manufacturing

One issue that has surfaced as the pharmaceutical industry responds to the US FDA’s recent discussion paper on manufacturing with AI machine learning models is the question of how to explain what the models are doing.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts